The Cancer Center (CORE) Support Grant (CCSG), will provide the necessary financial support that will assure quality administration of major programs in interdisciplinary basic and clinical cancer research, cancer education and training, cancer diagnosis and therapy, and community outreach. It is the intent of the OSUCCC to translate its own and other laboratories' observations into applicable clinical usage and to communicate existing and newly developed therapies, diagnostic procedures and prevention methods to the Ohio Valley Region. The CCSG will provide salary support for directors of vital programs and for key investigators necessary for further Center development. These individuals will collectively help to: (1) Optimally utilize and integrate the cancer efforts extant within the seven colleges at OSU engaged in cancer research; (2) Develop new programs, pilot studies and demonstration projects in cancer research, education, diagnosis and therapy within the OSUCCC and at community levels; (3) Encourage, aid, support and integrate community-run programs which are aimed to meet the needs of the respective areas; (4) Develop interdisciplinary activities between clinical and basic scientists to affect the translation process from laboratory to clinical application; (5) Communicate approved new developments in cancer diagnosis, therapy and rehabilitation to cooperating institutions throughout the Ohio Valley Region; (6) Establish effective cooperation with other existing and developing cancer centers including the National Cancer Institute. The OSUCCC will undergo significant development during the next five years that should culminate in solidification of research programs and development of an effective Cancer Control program for the region.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Ohio State University
Overall Medical
United States
Zip Code
Trn?ný, Marek; Verhoef, Gregor; Dyer, Martin Js et al. (2018) A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy. Haematologica 103:1351-1358
Bishop, Erin A; Java, James J; Moore, Kathleen N et al. (2018) Surgical outcomes among elderly women with endometrial cancer treated by laparoscopic hysterectomy: a NRG/Gynecologic Oncology Group study. Am J Obstet Gynecol 218:109.e1-109.e11
Kim, Miriam Y; Yu, Kyung-Rok; Kenderian, Saad S et al. (2018) Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia. Cell 173:1439-1453.e19
Malpeli, Giorgio; Barbi, Stefano; Tosadori, Gabriele et al. (2018) MYC-related microRNAs signatures in non-Hodgkin B-cell lymphomas and their relationships with core cellular pathways. Oncotarget 9:29753-29771
Niemas-Teshiba, Risa; Matsuno, Ryosuke; Wang, Larry L et al. (2018) MYC-family protein overexpression and prominent nucleolar formation represent prognostic indicators and potential therapeutic targets for aggressive high-MKI neuroblastomas: a report from the children's oncology group. Oncotarget 9:6416-6432
Sharpnack, Michael F; Chen, Bin; Aran, Dvir et al. (2018) Global Transcriptome Analysis of RNA Abundance Regulation by ADAR in Lung Adenocarcinoma. EBioMedicine 27:167-175
Tanaka, Ichidai; Sato, Mitsuo; Kato, Toshio et al. (2018) eIF2?, a subunit of translation-initiation factor EIF2, is a potential therapeutic target for non-small cell lung cancer. Cancer Sci 109:1843-1852
Slayton, William B; Schultz, Kirk R; Kairalla, John A et al. (2018) Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0622. J Clin Oncol 36:2306-2314
Bassett, Emily A; Palanichamy, Kamalakannan; Pearson, Mitchell et al. (2018) Calpastatin phosphorylation regulates radiation-induced calpain activity in glioblastoma. Oncotarget 9:14597-14607
Mardis, Elaine R (2018) New additions to the cancer precision medicine toolkit. Genome Med 10:28

Showing the most recent 10 out of 2602 publications